ArticleDrug and alcohol dependence reports2025

Phase 1b/2a safety study of lemborexant as an adjunctive treatment for insomnia to buprenorphine-naloxone for opioid use disorder: A randomized controlled trial.

Caitlin E Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.